Abstract
The median age of diagnosis for chronicmyeloidleukemia (CML) in India is 35years on the contrary to western literature which is 47years. The outcome of the elderly patient inCMLTKIera is not reported from the Indian population. However, Western literature suggests that use ofTKIalleviate the adverse impact of age in outcomes ofCML. This studywas carriedout to analyze the clinical profile and outcome of elderly, in comparison with younger patients withCML. We retrospectively analyzedCMLpatients treated at our department from January 2008 to December 2017. The data cutoff date was December 2018. The cohorts of 712 patientswere dividedinto two groups. Patients belonging to the age group of ≥ 60yearswere classifiedas the study group and those who were 18-60yearswere usedas controls. Patient's clinical history, examination and milestones in terms of achieving hematological, molecular responses and toxicity profile were also recorded. The total of 712 patients, 52 patients in the study group and 660 patients in the control group were treatedduring the study period. The study group was having moreco-morbiditiesthan the control group (15.3% vs. 4.5%). Patients having high-riskEUTOSscore were similar inboth groups (38.4% vs. 37.6%). The patients presented in blast phase were higher in the study group as compared to control group (9.6% vs. 6.36%) but the differences were not statistically significant. Rates of achieving a hematological response at 3months (85.1% vs. 86.89%) and the major molecular response at 18months (54.3% vs. 60.16%) were almost similar in both groups. However, hematological toxicity, muscle cramps and gastritis were reported more in elderly patients. The outcome ofCMLpatients inTKIera do not differ in elderly patients. However, toxicity profile wasnot significantlyinferior in elderly patients.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call